Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Recent developments in myelodysplastic syndromes

    ... in the United States (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and ...

    Research Article last updated 04/29/2016 - 11:34am.

  2. Myelodysplastic syndromes: Contemporary review and how we treat

    ... limited; they include the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with ...

    Research Article last updated 04/29/2016 - 1:05pm.

  3. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently ... myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is ...

    Research Article last updated 11/19/2015 - 8:32am.

  4. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents

    ... myelodysplastic syndrome (MDS) patients in whom azacitidine was the only treatment to demonstrate an overall survival ...

    Research Article last updated 09/29/2015 - 2:12pm.

  5. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

    ... reported to identify differential survival among azacitidine -treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a ...

    Research Article last updated 04/23/2014 - 12:10pm.

  6. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

    ... the impact of TP53 mutations in MDS treated with azacitidine (AZA) remains unclear. We analyzed TP53 mutations in 62 ...

    Research Article last updated 06/02/2014 - 11:17am.

  7. Personalized medicine for MDS

    ... accordingly. -Hypomethylating agents, such as azacitidine and decitabine , are standard care for older patients ... MDS who are not candidates for stem cell transplant.  Azacitidine in particular has been shown to have a survival advantage compared ...

    Research Review last updated 05/02/2016 - 9:44am.

  8. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

    ... and most responders lose response within 1-2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure of ... of MDS. Combination treatment strategies using an azacitidine backbone are demonstrating promising early results. Expanding the ...

    Research Article last updated 01/08/2014 - 9:15am.

  9. 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

    ... The efficacy and safety of azacitidine in elderly patients (aged >65 years) with myelodysplastic ... trials are reported. Thirty-eight patients with MDS received azacitidine (75 mg/m(2), schedule 5+2 +2): seven patients were classified as ...

    Research Article last updated 06/15/2012 - 2:13pm.

  10. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

    ... Hypomethylating agents (HMA), such as 5- azacitidine or decitabine , are currently used to treat patients ...

    Research Article last updated 05/26/2015 - 12:53pm.